Brief: Chinook Therapeutics Receives Orphan Drug Designation From European Commission For Atrasentan For Treatment Of Primary IgA Nephropathy

Chinook Therapeutics

14/12/2021 14:02

Dec 14 (Reuters) - Chinook Therapeutics Inc  KDNY.O :
    * CHINOOK THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FROM
EUROPEAN COMMISSION FOR ATRASENTAN FOR TREATMENT OF PRIMARY IGA
NEPHROPATHY
    * CHINOOK THERAPEUTICS INC - EXPECTS TO PRESENT DATA FROM
IGAN
PATIENT COHORT OF PHASE 2 AFFINITY STUDY IN FIRST HALF OF 2022
    * CHINOOK THERAPEUTICS - DATA FROM ONE OR MORE ADDITIONAL
COHORTS
OF AFFINITY STUDY EXPECTED IN SECOND HALF OF 2022

Source text for Eikon:  ID:nGNXb7JTB0 
Further company coverage:  KDNY.O 

 ((Reuters.Briefs@thomsonreuters.com;))